Summit Therapeutics SMMT
NASDAQ SMMT
$17.07 -0.76 (-4.29%)
As of: Nov 11, 2026 · 11:42 AM EST

Summit Therapeutics (SMMT) Long-Term Debt Repayments (2022 - 2024)

Updated

Summit Therapeutics' Long-Term Debt Repayments was $75.5 million in Q4 2024, unchanged from the prior quarter.

Analysis

Summit Therapeutics (SMMT) Long-Term Debt Repayments (2022 - 2024) Analysis & Trends

For FY2024, Long-Term Debt Repayments at Summit Therapeutics came in at $100 million, up 305.1% from FY2023.

  • Long-Term Debt Repayments shows a three-year compound annual growth rate of -3.1% (FY2021 to FY2024).
  • In earlier years, Long-Term Debt Repayments was $24.69 million in FY2023 (-1.3%), $25 million in FY2022 (-77.3%) and $110 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 1.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -4.91 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 3.05 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 19.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Summit Therapeutics 14.26 Bn 11.63 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 75.50 Mn
Sep 30, 2024 75.50 Mn
Mar 31, 2023 24.69 Mn
Sep 30, 2022 25.00 Mn
API Access

Summit Therapeutics Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=SMMT&period=max&api_key=YOUR_API_KEY